Sign in
Taking peopleNo phase

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

Key facts

Who runs it
Asian Institute of Gastroenterology, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
414 people, planned
Started
20 Dec 2025
Expected to end
12 Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Vonoprazan
  • Esomeprazole 40mg
Record updated
6 March 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Adults ≥18 years of age
  • Endoscopically confirmed LA grade B, C, or D reflux esophagitis
  • GERD symptoms (heartburn, regurgitation) for at least 4 weeks prior to enrollment
  • Willing to provide informed consent and comply with study procedures

Who cannot take part

  • Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 weeks
  • Prior esophageal surgery or radiation therapy
  • Use of NSAIDs, steroids, or anticoagulants affecting healing
  • Barrett's esophagus, esophageal stricture, or malignancy
  • History of PPI-refractory GERD or severe gastroparesis
  • Significant hepatic or renal impairment (ALT/AST >3× ULN, eGFR <30 mL/min)
  • Pregnant or breastfeeding women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Gerd

This trial is currently available in India.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary Objective

Read full original descriptionShow less

• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.

Secondary Objectives

* To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.

The 3 groups in the trial

  • To determine whether Vonaprazon 10mg heals grade B esophagitis at 8 weeksOther group

    Vonaprazon 10 mg heals gerd symptoms after 8 weeks

    Treatment: Vonoprazan

  • To determine whether Vonaprazon 20mg heals grade B esophagitis at 8 weeksOther group

    Vonaprazon 20 mg heals gerd symptoms after 8 weeks

    Treatment: Vonoprazan

  • To determine whether esomeprazole 40mg heals grade B esophagitis at 8 weeksOther group

    Esomeprazole 40mg heals gerd symptoms after 8 weeks

    Treatment: Esomeprazole 40mg

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Criteria questions
Built from NCT06953986, who can take part
Record updated
6 March 2026